RECRUITING

Strategies to AchieVe Viral Suppression for Youth With HIV

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Although there have been advances in antiretroviral treatment (ART) for HIV, adolescents and young adults living with HIV (AHIV) continue to have disparate HIV outcomes particularly viral suppression (VS), when compared to other populations likely related to multi-layered challenges (social determinants, cognitive development), system, and biomedical challenges including the reliance on oral ART as the only choice for HIV treatment. Given that approximately 1/3 of AHIV despite being in care fail to attain or sustain VS with resultant individual and public health risk, there is a need to develop real-world implementable interventions that can improve the participants virologic outcomes. The Strategies to AchieVe Viral Suppression for Youth with HIV (SAVVY) Study aims to 1) optimize personal ART choice by using the HIV-ASSIST clinical program to inform CHOICE counseling regarding an AHIV's preferred approach, including the possibility of long-acting injectable ART (LAI-ART); 2) facilitate access to the participants preferred choice through deploying a focused team to navigate barriers to attaining LAI-ART; and 3) decipher and address the patient, provider, and systemic barriers to the uptake and routinization of LAI-ART among AHIV by applying an implementation science framework and assessing cost-effectiveness providing critical data to support comprehensive approaches to optimizing ART and VS for AHIV, a key population identified in the Ending the HIV Epidemic in the United States Initiative.

Official Title

Strategies to AchieVe Viral Suppression for Youth With HIV (The SAVVY Study)

Quick Facts

Study Start:2024-11-10
Study Completion:2028-07-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06886971

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:12 Years to 30 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * prescribed ART,
  2. * willing to sign informed consent (including communication with one's primary HIV provider)
  1. * Relevant drug resistance mutations (per medical record) that compromises activity of Cabotegravir (CBG) + rilpivirine (RPV)
  2. * disallowed medications,
  3. * pregnancy.
  4. * Mental health, cognitive, or behavioral dysfunction that in the opinion of the site PI would impair participation;
  5. * severe illness/hospitalization at the time of enrollment,
  6. * plan to move away in the next 12 months.

Contacts and Locations

Study Contact

Allison Agwu, MD, SCM
CONTACT
410-614-3917
ageorg10@jhmi.edu

Principal Investigator

Allison Agwu, MD, SCM
PRINCIPAL_INVESTIGATOR
Johns Hopkins University

Study Locations (Sites)

Johns Hopkins University
Baltimore, Maryland, 21287
United States

Collaborators and Investigators

Sponsor: Johns Hopkins University

  • Allison Agwu, MD, SCM, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-11-10
Study Completion Date2028-07-31

Study Record Updates

Study Start Date2024-11-10
Study Completion Date2028-07-31

Terms related to this study

Keywords Provided by Researchers

  • adolescents
  • long-acting antiretroviral treatment
  • youth
  • young adu;ts
  • viral suppression
  • effectiveness

Additional Relevant MeSH Terms

  • Human Immunodeficiency Virus (HIV) Infection